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Abstract
BACKGROUND: Novel urinary biomarkers may have potential for early detection of acute kidney injury.
AIM: The aim of the study was to test two urinary biomarkers: Kidney injury molecule-1(KIM-1) and liver-type fatty 
acid binding protein (L-FABP) as markers of kidney injury following coronary angiography.
METHODS: This is a prospective non-randomized controlled trial, performed in two large teaching hospitals. Patients 
were recruited from the catheter lab or form nephrology outpatient clinics. In group (A), 100 patients with AKI on top of 
CKD after coronary angiography and Group B: Thirty-one patients with stable CKD as a control. KIM-1 and L-FABP 
were measured at base line and after 3 months. 
RESULTS: In group (A), 100 patients who had acute on top of CKD after coronary angiography, stage progression 
occurred in 15 patients in group (A) compared to two patients in group (B) (p = 0.28). The median change in eGFR 
after 3 months was not statistically significant between both groups (p = 0.8). Median baseline urinary liver-type fatty 
acid binding protein was higher in Group A compared to Group B (3.7 µg/g vs. 1.82µg/g). The change in L-FABP 
from baseline to 3 months was significant between both groups (p < 0.001). The median urinary concentrations of 
KIM-1 and L-FABP were higher at the end of the follow-up compared to base line values in both groups, (p < 0.000).
CONCLUSION: Urinary L-FABP correlates with kidney function decline in patients with acute on top of CKD after 
coronary angiography. Urinary levels of KIM-1 and L-FABP at 3 months increase significantly compared to baseline 
in patients with progressive CKD.
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Introduction
There is a cross-talk between acute kidney injury 
(AKI) and chronic kidney disease (CKD). CKD constitutes a 
substantial risk factor for AKI development; an AKI episode 
may result in worsening of CKD stage [1], [2], [3], [4], [5], [6]. 
CKD is associated with increased risk of cardiovascular 
disease and mortality, proportional to glomerular filtration 
rate decline [7], [8], [9]. In hospital mortality due to the 
development of contrast-induced nephropathy (CIN) 
after coronary angiography has improved [10], [11], [12]. 
However, data regarding the long-term outcome is lacking. 
The effect of CIN on outcome may persist for up to 
10 years [13].
A few biomarkers have shown variable 
sensitivity and specificity in early detection of CKD 
progression. CKD progression is classified using 
formulae to estimate glomerular filtration rate (eGFR) 
and measurement of proteinuria, both are easily 
available but limited by a number of fallacies [14].
Estimation of GFR reflects late functional 
changes; thus, eGFR is not considered an early marker 
of kidney damage. Plasma markers used in calculating 
eGFR (creatinine and urea) show significant increases 
only after about 50% of the GFR has been lost. In 
addition, these plasma markers are confounded by 
a large number of variables, including age, gender, 
race, muscle mass, muscle metabolism, hydration 
status, and medications. Furthermore, the enhanced 
tubular secretion of creatinine that is characteristically 
encountered at the lower rates of GFR results in an 
overestimation of renal function [15]. Recently, different 
plasma and urinary proteins have been evaluated as 
early biomarkers of CKD progression [15]. Each of these 
proteins has limitations that reduce reliability a as a sole 
biomarker of CKD progression. Kidney injury molecule 
(KIM-1) and liver-type fatty acid-binding protein (L-FABP) 
have shown a potential in a number of subclinical 
studies; this is much less the case with clinical studies 
on human participants [16], [17], [18], [19]. Our study 
aims to evaluate two urinary biomarkers in predicting 
CKD progression after coronary angiography. We used 
two biomarkers to enhance the prediction of progression.
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Patients and Method
Study population
This study is a prospective observational 
study conducted in the Emergency department at 
two large teaching hospitals Kasr Al Ainy University 
Hospitals and Zagazig University Hospitals during the 
period from January 2016 to December 2017. Ethics 
and Research Committee of the National Research 
Centre approved this protocol. One hundred and 
thirty-one adults enrolled in this study in two groups. 
Patients in Group A were recruited from the catheter-
lab after fulfilling the inclusion criteria for AKI after 
undergoing coronary angiography. Patients in Group 
B were recruited for nephrology clinics with different 
stages of CKD.
Group A (cases)
Hundred patients with different CKD stages, 
with diagnosis of AKI after coronary angiography 
were excluded from the study. Patients with end-
stage kidney disease (ESKD) or receiving renal 
replacement therapy (RRT) at the time of recruitment 
(before coronary angiography), were excluded from 
the study. Patients were recruited while in hospital 
and were then followed up in the nephrology out-
patients’ clinic.
Diagnostic criteria for CKD: According 
to KDIGO definition of CKD, as either eGFR 
< 60 ml/kg/min/1.73 m2 present for at least 3 months or 
the presence of kidney damage as denoted by structural 
or functional abnormalities other than decreased eGFR.
CKD stages were classified according to the 
international guideline group Kidney Disease Improving 
Global Outcomes (KDIGO) [20], classified into:
•	 Stage 1: Kidney damage with normal or 
increased GFR (>90 mL/min/1.73 m2)
•	 Stage 2: Mild reduction in eGFR (60–89 mL/
min/1.73 m2)
•	 Stage 3a: Moderate reduction in eGFR (45–59 
mL/min/1.73 m2)
•	 Stage 3b: Moderate reduction in eGFR (30–44 
mL/min/1.73 m2)
•	 Stage 4: Severe reduction in eGFR (15–29 
mL/min/1.73 m2)
•	 Stage 5: Kidney failure eGFR < 15 mL/min/1.73 
m2 or dialysis) 
AKI after coronary angiography was 
diagnosed based on RIFLE criteria (Table 1) as 
defined using the Risk, Injury, Failure, Loss, and End-
stage Kidney Disease [21]. Baseline values were 
the last pre-angiogram values, while peak values 
were obtained within 7 days following the coronary 
angiogram.
Table 1: RIFLE criteria for the diagnosis of acute kidney injury
Stage GFRa Criteria UOb Criteria
Risk SCrc increased 1.5-2 times baseline
or
GFR decreased >25%
UO < 0.5 mL/kg/h < 6 h
Injury SCr increased 2–3 times baseline
or
GFR decreased >50%
UO < 0.5 mL/kg/h >12 h
Failure SCr increased >3 times baseline
or
GFR decreased 75%
or
SCr ≥4 mg/dL; acute rise ≥0.5 mg/dL
UO < 0.3 mL/kg/h 24 h
(oliguria)
or
anuria 12 h
Loss of function Persistent acute renal failure: Complete loss 
of kidney function >4 wk (requiring dialysis)
Loss of function
ESRDd Complete loss of kidney function >3 mo 
(requiring dialysis)
ESRDd
aGFR, glomerular filtration rate, bUO, urine output, cSCr, serum creatinine, dESRD , end-stage renal disease
Group B (control): Thirty-one patients with 
different CKD stages with no episodes of AKI.
Informed consents had been obtained from all 
participants. Clinical assessment of participants included: 
Complete medical history and clinical examination 
including thorough cardiac examination. Estimated GFR, 
albumin creatinine ratio (ACR), urinary KIM-1, and L-FABP 
were measured at recruitment (baseline) and 3 months 
after angiography in Group A and as a base line and after 3 
months in the control group. Comorbid conditions such as 
diabetes mellitus and hypertension were recorded. Type 2 
diabetes was diagnosed using the criteria proposed by the 
American Diabetes Association. (ADA) 
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is 
defined as no caloric intake for at least 8 h.
OR
2-h PG ≥200 mg/dL (11.1 mmol/L) during 
OGTT. The test should be performed as described by 
the WHO, using a glucose load containing the equivalent 
of 75 g anhydrous glucose dissolved in water.*   
OR 
A1C ≥6.5% (48 mmol/mol). The test should be 
performed in a laboratory using a method that is NGSP 
certified and standardized to the DCCT assay.*   
 OR   
In a patient with classic symptoms of 
hyperglycemia or hyperglycemic crisis, a random 
plasma glucose ≥200 mg/dL (11.1 mmol/L).   
Fasting and 2 h post-prandial glucose 
levels in venous blood were measured with an 
autoanalyzer (Automated Beckman analyzer Au 
680). Hypertension was defined as mean systolic blood 
pressure ≥140 mm Hg, mean diastolic blood pressure 
≥90 mm Hg, a diagnosis of hypertension, or current use 
of antihypertensive medications.
Eligibility criteria
Eligible patients were CKD patients admitted 
to hospital from January 2016 to December 2017 who 
developed AKI after coronary angiography. The control 
arm included patients with stable CKD, followed up 
in the nephrology clinic during same period without 
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clinically evident AKI. The four-variable Modification 
of Diet in Renal Disease (MDRD) Study equation 
was used to estimate eGFR in our patients. The level 
of albuminuria was defined by the National Kidney 
Foundation definition (Table 2).
Table 2: Albumin to creatinine ratio defined by National Kidney 
Foundation as
Category ACR (mg/g) Terms
A1 30 Mildly increased
A2 30–300 Moderately increased
A3 >300 Severely increased
Exclusion criteria
As per protocol, we excluded patients 
receiving renal replacement therapy (dialysis or 
transplantation); inability to give a consent is considered 
as exclusion criteria. 
Coronary Angiography Study and 
Contrast Used
Coronary catheterizations were done using 
Philips (CV20, 2011-Netherland) and Siemens (Axiom 
Artis DFC 35875) with imaging speed 15 frame per 
second (fps). IOHEXOL (OMNIPAQUE)( General 
Electric Company) dye which is a nonionic, water-soluble 
radiographic contrast medium with a molecular weight of 
821.14 (iodine content 46.36%) was used in our patients.
Plasma and urine sample collection
Blood samples were obtained from patients after 
obtaining formal consent. Blood samples were centrifuged 
to obtain the plasma samples. Urine samples were 
obtained to measure urinary KIM-1 and L-FABP levels. 
Determination of urinary KIM-1 and L-FABP
KIM-1 was measured using microbead-based 
sandwich ELISA technique on Bioplex-200 platform 
(BioRad, Hercules, CA). L-FABP measured by two-step 
sandwich ELISA assay (CMIC, Tokyo, Japan).
Statistical analysis
Summary statistics were done. Numerical 
variables are presented as mean (SD) for normally 
distributed data and median (Minimum-Maximum) for 
non-normally distributed data. Categorical variables are 
presented as frequencies and percentages. Chi-squared 
test and Fischer’s exact test were used to categorical 
variables. Numerical data were tested for normality 
by the by the Shapiro–Wilk normality test. Normally 
distributed data were analyzed using independent 
samples t-test. Data found to be non-normally distributed 
were analyzed using the Mann–Whitney U-test. Paired 
samples were compared using the paired-samples t-test 
or the Wilcoxon signed-rank test as appropriate. Logistic 
regression analysis was performed to explore predictors 
of CKD stage progression. Predictors were tested for 
linearity before modeling. Data analysis was performed 
using Statistics/Data Analysis (STATA) version 13.1 
software.
Results
Study population
The baseline characteristics of both groups 
are shown in Table 1. The proportion of females was 
higher than males in both groups, with no significant 
difference between groups. The prevalence of diabetes 
was significantly higher in CKD who developed AKI after 
coronary angiography (Group A), 51% versus 29% in 
control group (p = 0.03). In addition, they had significantly 
higher systolic and diastolic values (p < 0.0001) and 
had more frequent heart failure (P=0.01) and they were 
significantly older than Group B, (p = 0.0001) as shown 
in Table 1.
Baseline eGFR and ACR levels
Those who had coronary angiography had 
significantly lower mean pre-angiographic eGFR, 
KIM-1 concentration, and significantly higher ACR 
and mean L-FABP concentration than control group 
(P<0.05). CKD stages distribution showed that most 
of the patients had Stage 3A CKD in both groups. 
However, more prevalent earlier stage (Stage 2 CKD), 
P=0.01 with a milder degree of microalbuminuria, and 
P=0.0001 was found in control group (Table 3).
Table 3: Baseline patients characteristics
Characteristics Cases n = 100 Control n = 31 p value
Age
Mean (SD)
71.14 (5.57) 61.16 (6.42) <0.0001
Gender
Male/Female 35/65 12/19 0.7
DM (N/%) 51 (51%) 9 (29%) 0.03
HF  (N/%) 47 (47%) 7 (22.6%) 0.01
Systolic BP 147.23 (13.77) 126.39 (9.79) <0.0001
Diastolic BP 78.89 (9.59) 71.03 (9.46) 0.0001
Baseline CKD stage
Stage_1_Mild_CKD (N/%) 0 0
Stage_2_Mild_CKD (N/%) 10 (10%) 9 (29%) 0.01
Stage_3A_Moderate_CKD (N/%) 65 (65%) 13 (41.9%)
Stage_3B_Moderate_CKD (N/%) 25 (25%) 8 (25.8%)
Stage_4_Mild_CKD (N/%) 0 0
Stage_5_End_Stage_CKD (N/%) 0 1 (3.2%)
Baseline ACR (mg/g)
< 30 9 (9%) 24 (77.4%) <0.0001
30-300 91(91%) 7 (22.6%)
>300 0 0
eGFR Median (IQR) 48 (44–53) 54 (42.5–60.2) 0.02
ACR Median (IQR) 52 (46–60) 23.1 (19.4–28.8) <0.0001
KIM ng/g  Mean (SD) 629.83 (119.55) 807.22 (114.02) <0.0001
L-FABP µg/g Median (IQR) 3.7 (3.14–4.15) 1.82 (1.72–1.85) <0.0001
DM: diabetes mellitus; HF: Heart failure; BP: Blood pressure; CKD: Chronic kidney disease. ACR: Albumin 
creatinine ratio; eGFR: Estimated glomerular filtration rate; KIM-1: Kidney injury molecule-1; L-FABP: Liver-
type fatty acid binding protein.
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AKI stage in the 100 patients who 
underwent angiography
Most of them (71%) developed a mild degree 
of AKI (Stage 1) after coronary angiography, followed by 
18% and 11% of severe and moderate AKI, respectively 
(Table 4).
Table  4:  AKI  classification  according  to  RIFLE  criteria  in 
patients underwent coronary angiography
Stage No %
Stage 1 (Risk of RIFLE criteria) 71 71%
Stage 2 (Injury of RIFLE criteria) 11 11%
Stage 3 (Failure of RIFLE criteria) 18 18%
Changes of eGFR, ACR, KIM-1, and L-FABP 
from baseline to the end of follow-up (after 3 months)
Non-significant changes in mean eGFR 
occurred in both groups at the follow-up, (Table 3), with 
no significant difference in its delta change between 
groups (Table 5).
The median urinary concentrations of KIM-1 
and L-FABP were increased significantly after 3 
months follow-up compared to base line values in 
both groups (p < 0.0001). As regard their delta change 
comparison, the rise in KIM-1 was significantly higher 
in Group A (Table 5). In addition, CKD patients who 
had coronary angiography had a significant increase 
of ACR after 3 months, p < 0.0001 (Table 3). Delta 
change in ACR revealed a significant higher elevation 
in Group A compared to Group B (p = 0.04) (Table 6).
Factors associated with progression of 
CKD stage
Progression of CKD stage occurred in 
15 patients from the Group 1 and only two patients 
from the control group (Group B). Logistic regression 
analysis of all the 130 patients revealed that higher 
systolic blood pressure as well as higher baseline eGFR 
are predictors of CKD stage progression, p = 0.01 
(Table 7). Twenty-five patients experienced CKD stage 
regression after 3 months of follow-up. The remaining 
patients had stable CKD over 3 months.
Discussion
In our study, we assessed the baseline 
kidney function by eGFR. CKD severity is a very 
strong risk factor for AKI development after coronary 
angiography. Our study cohort included different age 
groups not only elderly like previous two studies: 
Newsome et al and Parikh et al. [2], [3]. Our study 
is prospective in contrast to different retrospective 
studies in this field [22]. The study was done on 
non-dialysis patients, which represent the majority 
of CKD patients, to give a complementary data 
to other studies focusing on dialysis-requiring 
patients [23], [24], [25], [26].
Effect of baseline proteinuria on the association 
between AKI and subsequent CKD progression was 
shown in our study and the most important issue in our 
study is using simple urine analysis with low cost for 
KIM-1 and L-FABP not a pathological examination like 
some studies [25], [27].
 Reviewing literature, we found only one 
study addressing CKD progression after coronary 
angiography. They used serum creatinine and eGFR 
in determination of kidney function decline, which had 
several limitations [28]. In addition, it was a retrospective 
study; participants’ selection was limited to patients 
who had pre- and post-angiography serum creatinine 
measurements including measurements within 7 days 
of coronary angiography as part of their clinical care. 
Second, episodes of AKI and their severity in that study 
may have been misclassified due to our dependence on 
existing creatinine measurements captured following 
coronary angiography [28].
Patients who developed AKI were older, with 
several comorbidities including diabetes mellitus, a 
higher degree hypertension, with a higher prevalence 
of heart failure, all are well known risk factors for 
cardiovascular diseases which may necessitate coronary 
angiography as proved in many studies [29], [30]. In 
our study, CKD patients who developed AKI had a 
significantly lower pre-angiographic eGFR, a higher 
ACR and more advanced CKD stages at the baseline, 
as well a significant increase of ACR during subsequent 
measurement after 3 months of follow-up. However, 
more progression in CKD stage occurred in Group A 
(acute on top of chronic kidney disease) compared to 
only two patients in the Group B (control group). In the 
literature, reduced eGFR and increased proteinuria 
were found to be associated with risk of cardiovascular 
events, and death [7], [8], [9].
The pathophysiological relationship 
between CKD and AKI is complex and yet to be fully 
elucidated [31]. Progression of CKD after AKI episode 
could be explained by that, AKI on top of CKD causing 
Table 5: The change in Kidney functions and renal injury markers in cases versus control
Parameters Cases Control
Baseline Follow-up p value Baseline Follow-up p value
eGFR Median (IQR) 48 (44–53) 50 (45–52) 0.1 54 (42.5–60.2) 55.5  (45.5-60.2) 0.45
ACR Median (IQR) 52 (46–60) 68 (58–76) <0.0001 23.1  (19.4-28.8) 26.6 (20.5-32.2) 0.1
KIM Mean (SD) 629.83 (119.55) 677.84 (123.81) <0.0001 807.22 (114.02) 837.61 (103.48) <0.0001
L-FABP Median (IQR) 3.7  (3.14–4.15) 3.97 (3.27–4.53) <0.001 1.82  (1.72-1.85) 1.9  (1.85-1.94) <0.001
ACR: Albumin creatinine ratio, eGFR: Estimated glomerular filtration rate. KIM-1: Kidney injury molecule-1, L-FABP: Liver-type fatty acid binding protein.
 Soliman et al. Urinary Biomarkers in CKD Progression After Coronary Angiography
Open Access Maced J Med Sci. 2020 Oct 03; 8(B):1029-1035. 1033
Joseph Bonventre found that, KIM-1 promotes 
the scar tissue formation in chronic kidney disease and 
the kidney cells that produce it, maintains its expression 
over time in chronic kidney disease but this observation 
was unfortunately, found in mice [19]. A study found 
that, KIM-1 staining in the kidney biopsy of CKD 
patients with different etiology, correlated positively 
with morphological damage and negatively with renal 
function. Urinary KIM-1 levels measured in a subset 
of these patients were also negatively correlated with 
eGFR (r = -0.37; p = 0.016) [27].
In the literature, L-FABP levels were 
significantly higher in the group of patients with mild 
CKD who progressed to more severe disease in non-
diabetic CKD patients [15]. In another small study of 
patients with type-2 diabetes, urinary L-FABP levels 
were associated with degree of proteinuria[17]. These 
studies are consistent with our findings. 
Limitations of our study
This study has a number of limitations. First, 
we did not address the relation to mortality, to the effect 
of repeated AKI episodes and short time of follow-up. 
Second, there is a potential selection bias since the 
study is none randomized. There is a discrepancy 
between the numbers of cases to controls.
Strength of the study
This is a prospective study testing two novel 
urinary biomarkers using a simple urine sample.
Conclusion
Urinary L-FABP correlates with kidney function 
decline in patients with acute on top of CKD after 
coronary angiography at baseline compared to patients 
with stable CKD. Urinary level of KIM-1 and L-FABP at 
3 months increases significantly compared to baseline 
in patients with either stable or progressive CKD. The 
change in urinary L-FABP was more significant in 
patients with CKD progression.
Compliance with Ethical Guidance
All procedures performed in our study were in 
accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 
Helsinki Declaration and its later amendments or 
comparable ethical standards.
pathologic growth arrest in the proliferating tubules, 
failure to re-differentiate, and finally become atrophic. 
These abnormal tubules exhibit persistent, unregulated, 
and progressively increasing pro-fibrotic signaling along 
multiple pathways [32].
Table 6: Delta change in injury markers in cases versus 
control
Parameters Cases Control p value
∆ change in KIM 46 (35–56) 44 (40–47) 0.04
∆ change in LFABP 0.27 (0.12–0.35) 0.11 (0.08–0.13) <0.001
∆ change in eGFR 2 (-3–4) 1.7 (−2.4–3.4) 0.8
∆ change in ACR 15 (9–21) 4.4 (−5.4–9.7) <0.0001
ACR: Albumin creatinine ratio, eGFR: Estimated glomerular filtration rate, KIM-1: Kidney injury molecule-1, 
L-FABP: Liver-type fatty acid binding protein.
A mild non-significant increase in mean eGFR 
in both groups comes in agreement with study by Garg 
et al. concluded that an intervention that reduced the 
risk of mild to moderate acute kidney injury did not alter 
longer-term kidney function at 1 year [33].
Table 7: Predictors of CKD progression 
Predictors OR (95% Conf. Interval) p value
Age 1.3 (0.93–1.47) 0.9
Gender
Female 0.45 (0.16–1.26) 0.1
DM 2.39 (0.83–6.29) 0.1
CVD 2.24 (0.79–6.32) 0.1
Systolic BP 1.05 (1.01–1.09) 0.01
Diastolic BP 1.03 (0.97–1.08) 0.3
Baseline eGFR 1.08 (1.01–1.16) 0.01
Baseline ACR 1.01 (0.98–1.04) 0.6
Baseline KIM-1 0.99 (0.99–1.002) 0.4
Baseline L-FABP 1.3 (0.56–1.51) 0.3
DM: Diabetes mellitus, CVD: Cardiovascular disease, BP: Blood pressure; ACR: Albumin creatinine ratio, 
eGFR: Estimated glomerular filtration rate, KIM-1: Kidney injury molecule-1, L-FABP: Liver-type fatty acid 
binding protein.
In our study, patients who developed AKI 
had a significant lower mean KIM-1 and a significant 
higher mean L-FABP concentration at the baseline 
measurements compared to control group. These 
values are significantly increased by time at the end 
of the follow-up in both cases who developed AKI and 
in control group. The delta change in KIM-1 and ACR 
and L-FABP was significantly higher in cases than the 
control group. In either cases of CKD stage progression 
or regression, kidney injury biomarkers and ACR 
were significantly increased after 3 months. However, 
when we compare delta change of these biomarkers, 
we found non-significant results in relation to CKD 
stage progression. Some studies found that L-FABP 
correlated with degree of CKD progression [34], [35], 
while others found no significant correlation [36]. The 
reason for this discrepancy may be explained by the 
transient rise of L-FABP following renal injury. One 
study found that L-FABP best correlated with kidney 
injury as early as 4 h post-coronary angiography [37]. 
This denotes that the rise in L-FABP is transient.
Higher values of biomarkers in the control 
group may indicate possible early renal damage in 
the absence of persistent albuminuria and potential 
capabilities of urinary KIM-1 and L-FABP in early 
detection of renal injury among them. In a large health 
screening study, urinary excretion of L-FABP was found 
to be increased in subjects with hypertension and 
diabetes mellitus, even in the absence of overt kidney 
damage [18]. These comorbidities are also found in the 
control group.
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